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Abstract
Due to the ongoing development of clinical photodynamic therapy (PDT), the search contin-
ues for optimized photosensitizers that can overcome some of the side effects associated
with this type of treatment modality. The main protagonists being: post-treatment photosen-
sitivity, due to only limited cellular selectivity and post-treatment tumor regrowth, due to the
up-regulation of pro-inflammatory agents within the tumor microenvironment. A photosensi-
tizer that could overcome one or both of these drawbacks would be highly attractive to
those engaged in clinical PDT. Certain non-steroidal anti-inflammatory drugs (NSAIDs)
when used in combination with PDT have shown to increase the cytotoxicity of the treat-
ment modality by targeting the tumor microenvironment. Temoporfin (m-THPC), the gold
standard chlorin-based photosensitizer (PS) since its discovery in the 1980’s, has success-
fully been conjugated to non-steroidal anti-inflammatory compounds, in an attempt to ad-
dress the issue of post-treatment tumor regrowth. Using a modified Steglich esterification
reaction, a library of “iPorphyrins” was successfully synthesized and evaluated for their
PDT efficacy.
Introduction
Photodynamic therapy (PDT) is a still developing treatment modality for solid tumors of the
head, neck, throat, peritoneal cavity, skin as well as non-oncologic maladies such as psoriasis
or age-related macular degeneration [1,2]. The treatment involves the use of a three component
system comprising of a photosensitizer, light of specific wavelength and singlet oxygen. The
light causes the photochemical generation of cytotoxic oxygen species, among them most
prominent 1O2 by the photosensitizer within the target tissue. These reactive oxygen species
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contribute to cell death through both apoptotic and necrotic pathways [3]. PDT-mediated oxi-
dative stress has shown to include an array of immunologic responses and signal transduction
pathways whose impact on the efficacy of the treatment is still relatively unknown [4].
PDT as a treatment is continually evolving, with improvements in photosensitizer efficacy,
light source and dosimetry being made constantly [5,6]. There are a number of new photosen-
sitizers under investigation that have displayed improved clearance rates, targeting properties
or photophysical profile [7,8]. However, research and advancements in areas such as post-
treatment photosensitivity and tumor regrowth still need addressing [4]. Note, that the in vivo
toxicity of these PS is dependent on three factors: drug concentration and action, light and
oxygen concentration. Thus any pharmacological investigation is more complex than that of
‘classic’ chemotherapeutic drugs. On the other hand the multimodal mode of action through
reactive oxygen species mostly prevents resistance to develop.
PDT can induce inflammation and hypoxia that leads to the increased expression of pro-
survival and angiogenic molecules such as vascular endothelial growth factor (VEGF), survivin
and matrix metalloproteinases (MMPs) [9,10]. This up-regulation of pro-inflammatory mole-
cules within the tumor microenvironment can decrease the efficacy of the treatment due to the
occurrence of tumor regrowth [4,11].
Researchers have found that the prostaglandin-endoperoxide synthase 2 (COX-2) gene is
consistently over-expressed after a course of PDT and this result coincides with previous work
that demonstrated that PDT stimulates the release of prostaglandin E2 (PGE2) from macro-
phages and radiation induced fibrosarcoma (RIF) cells grown in culture [12]. This endogenous
prostaglandin (PG) release in mice exhibiting a systemic shock reaction after localized PDT
could be attenuated with NSAIDs [13,14]. Co-administration of celecoxib with PDT improved
the long-term tumoricidal activity whilst preserving normal tissue photosensitization [11,15].
Unfortunately, the administration of COX-2 inhibitors can cause a number of side effects,
which include cardiovascular or gastrointestinal injuries [16].
Studies indicate that the anti-tumor actions of coxibs such as celecoxib are independent of
COX-2 mediated mechanisms. It has been shown that a celecoxib analogue, 2,5-dimethyl cele-
coxib (DMC), displays cytotoxic properties comparable to celecoxib but without the COX-2 in-
hibitory activity. Gomer and coworkers were able to demonstrate the efficacy of DMC using a
C3H/BA murine mammary carcinoma model. Results showed that DMC increased both the
cytotoxicity and apoptosis in BA cells exposed to PDT treatment along with the induced ex-
pression of the pro-survival protein survivin [17]. PGE2 levels remained unchanged despite the
enhanced in vivo tumoricidal responsiveness to PDT, which means that DMC improved the ef-
ficacy of the treatment by causing an increase in apoptosis and anti-tumor activity.
Whilst there is strong evidence for improved efficacy with the co-administration of an anti-
inflammatory drug, to our knowledge, no research has been conducted on the administration
of a photosensitizer-anti-inflammatory agent conjugate [12,17]. We theorize that a conjugate
would undergo biological cleavage to give the PS and anti-inflammatory drug, which would ac-
commodate localized application of the anti-inflammatory agent and therefore an increased
therapeutic response. We here present initial data on the synthesis and biological evaluation of
such compounds.
Results and Discussion
Synthesis
Work on this project began with the continuation of studies conducted previously on the con-
trolled functionalization of porphyrin-based photosensitizers through simple nucleophilic sub-
stitution, esterification reactions or metal-catalyzed cross-coupling reactions. By using a simple
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aromatic anhydride 2, it was possible to selectively functionalize the porphyrin periphery to
the desired degree of substitution by monitoring the reaction time and equivalents used (Fig 1)
[18].
In an attempt to avoid any potential cardiovascular pitfalls caused by coxib based anti-in-
flammatories, a library of NSAIDs was chosen for the synthesis of these iPorphyrin conjugates
[16]. As the carboxylic acid functionality is present in most NSAIDs, and following on from
our work on the functionalization of known PSs, 5,10,15,20-tetrakis(3-hydroxyphenyl)porphy-
rin (m-THPP) and 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin (m-THPC), it seemed a logical
step to attempt the synthesis of these conjugates through esterification reactions. The ester
functionality is a bond that readily undergoes enzymatic cleavage and can be easily installed
into molecules. There are also wide arrays of NSAIDs that are commercially available and
therefore provide a large scope for variation for a library of conjugates.
We wished to use this newly developed methodology to functionalize Temoporfin (m-
THPC) [19,20,21], the gold standard ofmeso-substituted chlorin-based photosensitizers with
known molecules used to treat inflammation. Fenamic acid serves as a parent structure to a
number of different NSAIDs, e.g., tolfenamic acid and flufenamic acid. However, for an initial
screen of the utility of this approach we wished to optimize our synthetic pathway with a cheap
and readily available synthetic precursor, i.e. 5-hydroxyanthranilic acid, 4. This molecule con-
tains many of the functional groups present in fenamic acid and other NSAIDs and provides
an initial increase in complexity from the simple anhydride used in previous work [18].
The initial screen of conditions began with the use of a simple Fischer esterification reaction
to yield the chlorin ester product. A catalytic amount of H2SO4 was used with dry CH2Cl2 and
left to heat at reflux overnight. This reaction proved unsuccessful, even at increased tempera-
tures, and it seems that the chlorin macrocycle may be interfering with the electronics of the
phenol group by reducing the nucleophilicity of the hydroxy group and therefore inhibiting
the reaction with the carboxylic acid.
A Steglich reaction [22] using N,N'-dicyclohexylcarbodiimide (DCC) and 4-dimethylami-
nopyridine (DMAP) as coupling partners was attempted in DMF at room temperature. Initial
results from this reaction appeared promising, however, the yield for the reaction was low and
the presence of an insoluble N-acyl urea made purification of the product problematic.
Fig 1. Controlled functionalization of them-THPP photosensitizer scaffold using benzoic anhydride.
doi:10.1371/journal.pone.0125372.g001
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A suitable substitute for DCC is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro-
chloride (EDC), a preferred alternate cross-coupling agent due to its solubility in water [23].
This was used in the presence of a catalyst, DMAP, in DMF and at room temperature with no
observable esterification occurring. The reaction was reattempted at elevated temperatures and
no reaction product was observed by TLC and NMR.
Hydroxybenzotriazole (HOBt) may also be used in conjunction with EDC as a carboxy-
activating agent [24,25]. It reacts with the O-acylurea formed from the reaction between the
carboxylic acid group of the NSAID and the EDC, to form an activated ester, which can be
isolated or used in situ [26,27]. Generation of this activated ester and subsequent addition of
the chlorin photosensitizer allowed for the formation of the ester conjugates 8a and 8b. By
monitoring the reaction time and equivalents, one is able to maximize the amount of mono-
functionalized chlorin in the reaction mixture in comparison to the higher order derivatives.
Thin-Layer chromatography showed a distinctive degree of substitution pattern, with the tetra-
functionalized derivative having the highest Rf and the unsubstituted chlorin having the lowest.
Following on from the success of these reaction conditions, the scope of the synthesis was
investigated by using a variety of NSAIDs to create a small library of conjugates. Ibuprofen,
(S)-2-(4-(2-methylpropyl)phenyl)propanoic acid 5 and fenamic acid, i.e. 2-(phenylamino)ben-
zoic acid 6 were chosen as suitable initial candidates for the screen due to similarities in struc-
ture to anthranilic acid and also their prolific record as agents used in the treatment of
numerous inflammatory diseases [28,29,30]. Both NSAIDs readily conjugated to the chlorin
scaffold in a controlled and predictable fashion and altering the reaction time and equivalents
of reagents used could maximize the degree of functionalization and achieve conjugates 9a, 9b,
10a and 10b in good yields as per the Fig 2.
The final section of this library of conjugates was completed with the introduction of
Nicotinic acid 7 onto the chlorin periphery. Nicotinic acid, whilst traditionally clinically imple-
mented to influence cholesterol levels, has been shown to have quite promising anti-inflamma-
tory properties in cases of atherosclerosis [31,32]. Unfortunately, nicotinic acid did not readily
undergo conjugation with the chlorin photosensitizer under these optimized conditions. How-
ever, after investigation into a number of different bases and modified procedures, it was found
that pyridine and EDC worked to yield the mono- (11a) and tetrafunctionalized (11b) deriva-
tives in yields comparable to the previous conjugates.
This library has shown thatm-THPC is tolerable of standard reaction conditions, work-
ups and chromatography without subsequent oxidation to the parent porphyrin derivative;
evidence that contradicts historical perceptions of this molecule. NMR assignment of the
mono-functionalized compounds proved extremely difficult due to the presence of a statistical
mixture of the possible regiochemical isomers. These compounds were prepared for compara-
tive purposes to gain some initial insight in the influence of the substituent pattern and amphi-
philicity on the uptake. These regioisomers are formed because of the reduced double bond
located on the pyrrole A ring and they cannot be resolved using standard chromatographic
procedures. This mixture is consistent with literature reports of similar systems, however,
where possible, the β and inner pyrrolic protons were used as diagnostic peaks [33,34,35].
Thus, high-resolution mass spectrometry (HRMS) analysis acted as our main analytical tool
for confirmation of product formation and NMR was used for the assignment of the dominant
regioisomer being presented in the experimental section.
Singlet Oxygen Studies
For any molecule to be considered a potential clinical PS, they must possess a high quantum
yield of 1O2. To evaluate the
1O2 production capability of our library of conjugates, compounds
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were subjected to a crude assay in order to estimate their 1O2 generation [36]. Their production
of 1O2 was determined through the monitoring of the change in the absorption at 410 nm of
the dye 1,3-diphenylisobenzofuran (DPBF) in solution. DPBF has an absorbance maximum at
Fig 2. Modified Steglich reaction with a variety of NSAIDs to afford novel chlorin-NSAID photosensitizers. *Only one of the possible isomers
is shown.
doi:10.1371/journal.pone.0125372.g002
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410 nm and readily undergoes a ring opening reaction in the presence of 1O2. One can monitor
the reduction of this band over time and graph an estimate of 1O2 production. Compounds 9b
and 10a were taken as representative samples of the library and screened for their singlet oxy-
gen production capabilities. The results obtained for compounds 9b and 10a from this assay
were then compared to results obtained with the known 1O2 producerm-THPC to give a rela-
tive indication of their 1O2 producing potential.
Compounds 9b and 10a were dissolved in an aerated solution of DPBF in DMF and irradi-
ated with white light and the intensity of the DPBF’s absorption band was monitored over time
using UV-vis spectroscopy. Both compounds showed good production of 1O2, as per Fig 3,
however not to the same extent asm-THPC.
Biological Testing
Compounds 8a-11b underwent biological testing to ascertain their localization and cytotoxic
properties using esophageal carcinoma OE33, esophagus adenocarcinoma, and well-differenti-
ated SKGT-4 human cell lines (Fig 4). All compounds were successfully taken up into the cell
and in accordance with previous research conducted with the same PS core, appear to localize
in the endoplasmic reticulum (ER) and Golgi apparatus. The compounds were then subjected
to a colorimetric MTS assay to assess their cytotoxicity. The compounds were tested over a
range of concentrations with an illumination period of 2 min [37]. Unfortunately, none of the
conjugates exhibited any phototoxic effect, which may be due to the relatively short illumina-
tion period. As per the graph in Fig 3,m-THPC has a considerably large yield of 1O2 after 2
min of illumination, whereas the conjugates tested only begin to become comparable tom-
THPC after an illumination period of 12 min.
Fig 3. Graph displaying the reduction in absorbance of DPBF at 410 nm over time due to the production of 1O2 by 9b and 10a.
doi:10.1371/journal.pone.0125372.g003
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Conclusions
We have successfully synthesized a small library of chlorin conjugated NSAIDs through the
controlled functionalization of the chlorin core through a modified Steglich reaction. This
methodology proved to be simple, robust and produced mono- and tetra-functionalized conju-
gates in reasonable yields and few synthetic steps. This new reaction pathway also highlights
the ability ofm-THPC, a molecule historically perceived to be difficult to work with, to under-
go standard chemical manipulations without subsequent oxidation to its parent porphyrin
derivative. All conjugates successfully entered into the cells and whilst no cytotoxicity was ob-
served, this work has served as an initial entry point into the field of PDT and post-treatment
inflammation. We hope to fine-tune the cytotoxicity of these porphyrins by synthesizing a larg-
er library of conjugates using more regulatory approved anti-inflammatories. These will then
undergo a thorough assessment of their PDT efficacy over a range of irradiation times as sug-
gested by the 1O2 production assay data we have obtained above. It is hoped that this approach
will further progress the reduction of post-PDT inflammation and tumor regrowth, and there-
fore improve the overall efficiency of PDT. This library of conjugates could also undergo in
vivo experiments in mice in conjunction with researchers in the biochemists. Ideally, these po-
tential collaborators would administer one of the conjugates intravenously and through the use
of Western-blot analysis, observe reduced levels of the pro-inflammatory molecules associated
with this tumor regrowth.
Materials and Methods
All commercial chemicals used were of analytical grade and were supplied by Sigma Aldrich,
Frontier Scientific, Inc. and Tokyo Chemical Industry (TCI) and used without further purifica-
tion unless otherwise stated. Anhydrous THF and diethyl ether were obtained via distillation
Fig 4. OE33 and SKGT-4 cells stained with compounds 9a-11b (red), nuclear dye Hoechst 33342
(blue), F-actin dye Phalloidin 490 (green): (a) 8a 30 μM, SKGT-4; (b) 9b OE33 40 μM; (c) 10a SKGT
40 μM; (d) 11b OE33 40 μM. All photographs were taken at a magnification of 10×.
doi:10.1371/journal.pone.0125372.g004
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over sodium/benzophenone and dichloromethane dried was obtained via distillation over
P2O5. Cell lines were obtained from
1H and 13C NMR spectra were recorded on a Bruker dpx
400 (400 MHz for 1H NMR; 100.6 MHz for 13C NMR), Agilent MR400 (400.13 MHz for 1H
NMR and 100.61 MHz for 13C NMR) and Bruker AV 600 (600 MHz for 1H NMR; 150.9 MHz
for 13C NMR. High-Resolution Mass-Spectrometry (HRMS) experiments were measured on a
Waters MALDI Q-TOF Premier in positive and negative mode with DCTB (trans-2[3-4-tert-
butylphenyl)-2-2-methyl-2-propenylidene]malononitril) as the MALDI matrix. Melting points
were acquired on a Stuart SMP-10 melting point apparatus and are reported uncorrected. Thin
layer chromatography (TLC) was performed on silica gel 60 (fluorescence indicator F254;
Merck) pre-coated aluminium sheets. Flash chromatography was carried out using Fluka silica
gel 60 (230–400 mesh) and aluminium oxide (neutral, activated with 6.5% H2O, Brockmann
Grade III). Photophysical measurements were performed using EtOAc, THF, and CH2Cl2 as
solvents with UV-vis absorption measurements performed with a Shimadzu Multispec-1501
Spectrometer.
The human esophageal squamous cell carcinoma cell line OE21 and the human adenocarci-
noma cell lines SKGT-4 and OE33, derived from Barrett’s esophagus, were purchased from the
European Collection of Cell Cultures (ECACC) [38,39].
Biological Testing
General procedure for cell cultures and the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) cell proliferation assay: Cell lines were
seeded at a concentration of 8 × 104 cells per mL into sterile 96-well plates, left to attach over-
night and treated. To previously prepared 96-well assay plates containing cells in 100 μL of cul-
ture medium, the test compounds at different concentrations and appropriate controls were
added. After incubation for 24 h the medium was removed and changed for fresh one, dark
controls were left in the dark for next 24 h. To assess the phototoxicity, the rest of the plates
were illuminated for 2 min and incubated for 24 h. Finally, 20 μL of MTS dye solution was
added to each well of the dark controls and illuminated plates and these were incubated for 3 h
and the absorbance was recorded at 470 nm using a 96-well plate reader. Cell lines were seeded
at a concentration of 3 × 104 cells per mL into sterile 96-well plates leaving them for 24 h to at-
tach. For imaging experiments, the cell culture medium was removed, replaced with freshly
prepared solutions of the porphyrins 8–11 of various concentrations in the medium and incu-
bated at 37°C under 5% CO2 for 24 h. After that the medium was removed and the cells were
fixed with 4% paraformaldehyde (PFA) in medium and then washed with phosphate-buffered
saline (PBS). Fluorescent images were collected and analyzed by high content screening and
imaging technique (IN Cell 1000 instrument, GE Healthcare). Full details on the cell cultures
and treatment, cell proliferation assay, high content imaging and analysis, statistical treatment,
and illumination protocol are as given in Vaz et al. [37].
General Synthetic Procedure A
Monofunctionalization ofm-THPC: EDC (2 eq.), HOBt (2 eq.), K2CO3 (2 eq.) were added to a
50 mL round bottomed flask and charged with DMF (10 mL). The appropriate anti-inflamma-
tory agent (2–3 eq.) was added and the reaction was allowed to stir for 60 minutes under argon.
m-THPC (1 eq.) was added to the mixture and the reaction was monitored by TLC and once
significant conversion to the mono-substituted species was achieved, the reaction was termi-
nated through the addition of CH2Cl2 (50 mL). The crude reaction mixture was washed with
distilled water (1×30 mL), sat. aq. NaHCO3 (1×30 mL), brine (1×30 mL), and distilled water
Anti-Inflammatory Porphyrin Conjugates
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(2×30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporat-
ed under reduced pressure.
General Synthetic Procedure B
Tetrafunctionalization ofm-THPC:m-THPC (1 eq.) was added to a round-bottomed flask
(50 mL) and charged with DMF (10 mL) and K2CO3 (5–20 eq.). The reaction was left to stir for
60 minutes under argon before the appropriate functionalization reagent (10–20 eq.) was
added. The reaction mixture was monitored by TLC and once full conversion to the desired de-
gree of substitution was observed the reaction was terminated through the addition of CH2Cl2
(50 mL). The work-up proceeds as per general procedure A.
5,10,15-Tris(3-hydroxyphenyl)-20-[3-phenyl(2-amino-
5-hydroxybenzoate]chlorin / 5,15,20-Tris(3-hydroxyphenyl)-10-[3-phenyl
(2-amino-5-hydroxybenzoate]chlorin (8a)
The compound was synthesized using general procedure A: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (46.0 mg, 0.294 mmol), HOBt (39.7 mg,
0.294 mmol), K2CO3 (40.6 mg, 0.294 mmol) and 5-hydroxyanthranilic acid (44.9 mg, 0.297
mmol) was allowed stir for 4 h. NMR indicates a mixture of regioisomers. Column chromatog-
raphy on silica gel using CH2Cl2/n-hexane/MeOH (3:1:0.2, v/v/v) produced a mixture of
monofunctionalized regioisomers in a yield of 43.1 mg of purple crystals (0.053 mmol, 36%).
Analytical data: m.p.>300°C; Rf = 0.43 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400
MHz, [(CD3)2SO], 25°C): δH = -1.68 (s, 1H,-NH), -1.61 (s, 1H,-NH), 4.14 (s, 4H, Hβ), 6.84 (m,
2H, Ar-H), 7.14 (m, 1H, Ar-H), 7.24 (m, 9H, Ar-H), 7.47 (m, 7H, Ar-H), 8.22 (d, 3JH-H =
4.93 Hz, 2H, Hβ), 8.3 (s, 2H,Hβ), 8.61 (d,
3JH-H = 4.93 Hz, 2H, Hβ), 9.24 (s, 1H, OH), 9.77
(app d, 3H, OH) ppm; 13C NMR (100 MHz, [(CD3)2SO], 25°C): δ = 36.1, 115.1, 115.5, 119.7,
120.4, 122.3, 123.5, 123.7, 126.2, 128.3, 129.2, 131.7, 139.8, 141.5, 142.9, 143.3, 156.9, 157.2,
164.2 ppm; UV/Vis (EtOAc): λmax (lg ε) = 419 (6.78), 519 (5.67), 545 (5.48), 598 (5.28),
651 nm (6.03); HRMS (MALDI) calcd for [M]+ C51H37N5O6 815.2744, found 815.2731.
5,10,15,20-Tetrakis-[3-phenyl(2-amino-5-hydroxybenzoate)]chlorin (8b)
The compound was synthesized using general procedure B: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (273 mg, 1.76 mmol), HOBt (238 mg,
1.76 mmol), K2CO3 (243 mg, 1.76 mmol) and anthranilic acid (269 mg, 1.76 mmol) was al-
lowed stir for 20 h. Recrystallization from ethyl acetate:n-hexane yielded 109 mg of purple crys-
tals (0.089 mmol, 61% yield). m.p.> 300°C; Rf = 0.91 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H
NMR (400 MHz, CDCl3, 25°C): δ = -1.54 (s, br, 2H,-NH), 4.16 (s, 4H,Hβ), 7.05 (m, 4H, Ar-H),
7.14 (m, 4H, Ar-H), 7.22 (m, 8H, Ar-H), 7.29 (m, 8H, Ar-H) 7.42 (m, 4H, Ar-H), 7.55 (m, 4H,
Ar-H), 8.59 (d, 3JH-H = 4.38 Hz, 2H,Hβ), 8.63 (d,
3JH-H = 4.38 Hz, 2H,Hβ) ppm;
13C NMR
(100 MHz, CDCl3, 25°C): δ = 35.9, 114.3, 115.0, 115.4, 117.9, 119.6, 120.9, 121.3, 122.8, 123.2,
123.5, 126.3, 128. 2, 128.9, 129.1, 139.7, 139.9, 141.7, 142.3, 156.6, 157.1, 168.2 ppm; UV/Vis
(EtOAc): λmax (lg ε) = 420 (6.62), 517 (5.33), 545 (5.13), 598 (5.28), 651 nm (5.89); HRMS
(MALDI) calcd for [M]+ C72H52N8O12 1220.3705, found 1220.3693.
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5,10,15-Tris(3-hydroxyphenyl)-20-[3-(2-{4-iso-butylphenyl}propanoate)
phenyl]chlorin / 5,15,20-Tris(3-hydroxyphenyl)-10-[3-(2-{4-iso-
butylphenyl}propanoate)phenyl]chlorin (9a)
The compound was synthesized using general procedure A: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (46.0 mg, 0.294 mmol), HOBt (39.7 mg,
0.294 mmol), K2CO3 (40.6 mg, 0.294 mmol) and ibuprofen (60.6 mg, 0.297 mmol) was allowed
stir for 4 h. NMR indicates a mixture of regioisomers. Column chromatography on silica gel
using CH2Cl2/n-hexane/MeOH (3:1:0.2, v/v/v) produced a mixture of monofunctionalized
regioisomers in a yield of 45 mg of purple crystals (0.05 mmol, 35%). Analytical data: m.p.
>300°C; Rf = 0.37 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400 MHz, [(CD3)2SO],
25°C): δH = -1.67 (s, 2 H.-NH), 1.12 (m, 9H,-CH3), 2.04 (s, 2 H,-CH2), 3.00 (m, 2 H,-CH), 4.13
(s, 4H, Hβ), 7.07 (m, 2 H, Ar-H), 7.13 (m, 2 H, Ar-H), 7.28 (m, 6H, Ar-H), 7.46 (m, 10H, Ar-
H), 8.21 (d, 3JH-H = 4.86 Hz, 2H,Hβ) 8.35 (s, 2H,Hβ), 8.60 (d,
3JH-H = 4.86 Hz, 2H,Hβ), 9.75 (s,
3H,-OH) ppm; 13C NMR (100 MHz, [(CD3)2SO], 25°C): δ = 8.1, 9.0, 31.1, 35.8, 46.0, 55.3,
112.5, 114.1, 115.1, 115.3, 117.8, 119.7, 121.5, 122.4, 123.4, 123.9, 125.7, 128.3, 128.5, 129.6,
129.9, 132.2, 132.2, 134.6, 140.2, 142.9, 143.8, 151.9, 157.4, 168.0 ppm; UV/Vis (EtOAc): λmax
(lg ε) = 420 (6.68), 519 (5.54), 545 (5.34), 597 (5.17), 651 nm (5.92); HRMS (MALDI) calcd for
[M]+ C57H48N4O5 868.3625, found 868.3613.
5,10,15,20-Tetrakis-[3-phenyl(2-{4-iso-butylphenyl}propanoate)]chlorin
(9b)
This target was synthesized using general procedure B: a 50 mL round bottom flask containing
10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (273 mg, 1.76 mmol), HOBt (238 mg, 1.76 mmol),
K2CO3 (243 mg, 1.76 mmol) and ibuprofen (363 mg, 1.76 mmol) was allowed stir for 18 h. Re-
crystallization from ethyl acetate:n-hexane yielded 140 mg of purple crystals (0.096 mmol, 65%
yield). m.p.>300°C; Rf = 0.91 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400MHz, CDCl3,
25°C): δH = -1.57 (s, 2 H.-NH), 0.81 (m, 36H,-CH3), 1.25 (s, 8 H,-CH2), 2.37 (m, 8 H,-CH), 4.12
(s, 4H,Hβ), 7.07 (m, 8 H, Ar-H), 7.28 (m, 8 H, Ar-H), 7.28 (m, 6H, Ar-H), 7.46 (m, 10H, Ar-H),
8.21 (d, 3JH-H = 4.86 Hz, 2H,Hβ) 8.35 (s, 2H,Hβ), 8.60 (d,
3JH-H = 4.86 Hz, 2H,Hβ) ppm;
13C
NMR (100 MHz, CDCl3, 25°C): δ = 19.0, 22.1, 30.3, 44.7, 114.6, 114.7, 114.8, 119.3, 119.4, 120.3,
123.3, 123.4, 123.7, 127.6, 129.6, 137.8, 140.4, 144.6 176.2 ppm; UV/Vis (EtOAc): λmax (lg ε) =
419 (6.71), 518 (5.58), 545 (5.38), 597 (5.16), 651 nm (5.96); HRMS (MALDI) calcd for [M]+
C96H96N4O8 1432.7228, found 1432.7215.
5,10,15-Tris(3-hydroxyphenyl)-20-[3-phenyl(2-(phenylamino)benzoate]
chlorin / 5,15,20-Tris(3-hydroxyphenyl)-10-[3-phenyl(2-(phenylamino)
benzoate]chlorin (10a)
The compound was synthesized using general procedure A: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (46.0 mg, 0.294 mmol), HOBt (39.7 mg,
0.294 mmol), K2CO3 (40.6 mg, 0.294 mmol) and fenamic acid (62.6 mg, 0.297 mmol) was al-
lowed stir for 3 h. NMR indicates a mixture of regioisomers. Column chromatography on silica
gel using CH2Cl2/n-hexane/MeOH (3:1:0.2, v/v/v) produced a mixture of monofunctionalized
regioisomers in a yield of 50.6 mg of purple crystals (0.064 mmol, 45%). Analytical data: m.p.
>300°C; Rf = 0.43 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400 MHz, [(CD3)2SO],
25°C): δH = -1.63 (s, 2H,-NH), 4.13 (s, 4H, Hβ), 6.86 (m, 2H, Ar-H), 7.06 (m, 3H, Ar-H), 7.23
(m, 8H, Ar-H), 7.31 (m, 3H, Ar-H), 7.46 (m, 8H, Ar-H), 7.67 (s, 1H, Ar-H), 8.21 (d, 3JH-H =
4.93 Hz, 2H, Hβ), 8.61 (m, 2H,Hβ), 8.85 (d,
3JH-H = 4.93 Hz, 2H,Hβ), 9.70 (s, 2H,-OH), 9.86 (s,
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1H,-OH) ppm; 13C NMR (100 MHz, [(CD3)2SO], 25°C): δ = 36.1, 114.7, 118.3, 119.7, 121.5,
122.2, 122.3, 122.6, 123.9, 125.4, 128.3, 128.5, 129.9, 131.9, 132.0, 132.4, 134.5, 134.6, 142.8,
143.8, 149.5, 152.0, 156.3, 167.5 ppm; UV/Vis (EtOAc): λmax (lg ε) = 420 (6.11), 519 (5.69),
544 (5.50), 597 (5.30), 645 nm (6.07); HRMS (MALDI) calcd for [M]+ C57H41N5O5 875.3108,
found 875.3117.
5,10,15,20-Tetrakis[3-phenyl(2-(phenylamino)benzoate]chlorin (10b)
The compound was synthesized using general procedure B: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (273 mg, 1.76 mmol), HOBt (238 mg,
1.76 mmol), K2CO3 (243 mg, 1.76 mmol) and fenamic acid (257 mg, 1.76 mmol) was allowed
stir for 20 h. Recrystallization from ethyl acetate:n-hexane yielded 178 mg of purple crystals
(0.122 mmol, 83% yield). m.p.>300°C; Rf = 0.91 [CH2Cl2/n-hexane/MeOH (3:1:0.2)]
1H
NMR (400 MHz, CDCl3, 25°C): δ = -1.65 (s, br, 2H,-NH), 4.17 (s, 4H,Hβ), 7.24 (m, 5H, Ar-H),
7.47 (m, 8H, Ar-H), 7.62 (m, 8H, Ar-H), 7.74 (m, 4H, Ar-H) 7.82 (m, 8H, Ar-H), 8.04 (m, 4H,
Ar-H), 8.37 (m, 3H, Ar-H), 8.5 (m, 4H, Ar-H), 8.64 (m, 4H, Ar-H), 8.85 (m, 4H, Ar-H), 9.30 (s,
6H,Hβ), 9.75 (s, br, 4H,-NH) ppm;
13C NMR (100 MHz, CDCl3, 25°C): δ = 36.4, 112.6, 114.6,
114.8, 114.9, 115.5, 118.6, 121.5, 122.2, 122.3, 122.5, 129.1, 129.5, 129.6, 129.7, 129.9, 130.5,
151.9, 156.4, 157.6, 158.5, 167.9 ppm. UV/Vis (EtOAc): λmax (lg ε) = 420 (6.90), 518 (5.78),
545 (5.59), 598 (5.39), 651 nm (6.16); HRMS (MALDI) calcd for [M]+ C96H68N8O8 1460.5160,
found 1460.5149.
5,10,15-Tris(3-hydroxyphenyl)-20-[3-phenyl(nicotinate]chlorin /
5,15,20-Tris(3-hydroxyphenyl)-10-[3-phenyl(nicotinate]chlorin (11a)
The compound was synthesized using general procedure B: a 50 mL round bottom flask
containing 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (46.0 mg, 0.294 mmol), Pyridine
(0.3 mL) and nicotinic acid (36.2 mg, 0.297 mmol) was allowed stir for 2 h. NMR indicates a
mixture of regioisomers. Column chromatography on silica gel using CH2Cl2/n-hexane/
MeOH (3:1:0.2, v/v/v) produced a mixture of monofunctionalized regioisomers in a yield of
49.6 mg of purple crystals (0.063 mmol, 43%). Analytical data: m.p.>300°C; Rf = 0.43
[CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400 MHz, [(CD3)2SO], 25°C): δH = -1.67 (s,
2H,-NH), 4.13 (s, 4H,Hβ), 7.06 (d, 2H,
3JH–H = 8.33 Hz, Ar-H), 7.14 (d, 2H,
3JH–H = 8.33 Hz,
Ar-H), 7.25 (m, 8H, Ar-H), 7.66 (m, 8H, Ar-H), 8.21 (d, 3H, 3JH–H = 4.82 Hz, Hβ), 8.63 (d, 3H,
3JH–H = 4.82 Hz, Hβ), 9.21 (s, br, 3H,-OH) ppm;
13C NMR (100 MHz, [(CD3)2SO], 25°C): δ =
36.7, 115.5, 120.4, 122.3, 126.2, 128.3, 129.2, 131.7, 139.8, 141.5, 142.9, 143.3, 156.9, 157.2,
165.4 ppm; UV/Vis (EtOAc): λmax (lg ε) = 420 (6.44), 507 (5.51), 534 (5.31), 589 (5.01),
645 nm (5.94); HRMS (MALDI) calcd for [M]+ C50H35N5O5 785.2638, found 785.2615.
5,10,15,20-Tetrakis[3-phenyl(nicotinate]chlorin (11b)
The compound was synthesized using general procedure B: a 50 mL round bottom flask con-
taining 10 mL of DMF, 1 (100 mg, 0.147 mmol), EDC (273 mg, 1.76 mmol), pyridine (1 mL)
and nicotinic acid (216 mg, 1.76 mmol) was allowed stir for 20 h. Recrystallization from ethyl
acetate:n-hexane yielded 113 mg of purple crystals (0.102 mmol, 70% yield). m.p.>300°C; Rf =
0.91 [CH2Cl2/n-hexane/MeOH (3:1:0.2)];
1H NMR (400 MHz, CDCl3, 25°C): δH = -1.67 (s, br,
2H,-NH), 4.17 (s, 4H,Hβ), 7.60 (m, 8H, Ar-Hchlorin), 7.83 (m, 8H, Ar-Hchlorin), 8.04 (m, 4H, Ar-
HNico), 8.49 (m, 4H, Ar-HNico), 8.85 (m, 8H, Ar-HNico) 9.29 (s, br, 6H,Hβ) ppm;
13C NMR
(100 MHz, CDCl3, 25°C): δ = 114.51, 119.52, 121.27, 127.46, 128.41, 155.85, 171.01 ppm; UV/
Vis (EtOAc): λmax (lg ε) = 420 (6.44), 507 (5.51), 534 (5.31), 589 (5.01), 645 nm (5.94); HRMS
(MALDI) calcd for [M]+ C68H44N8O8 1100.3282, found 1100.3292.
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